Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in Acute Aortic Syndrome Surgery (PANDA III)
NCT04699279Recruiting
- Sponsor
- Nanjing Medical University
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of rosuvastatin in Acute aortic syndrome (AAS) and aortopathy, sponsored by Nanjing Medical University. Primary endpoint: Aortic adverse events at 3 months. Started Jan 2021; status: recruiting.
02
Drugs
rosuvastatin
03
Conditions
Acute aortic syndrome (AAS)aortopathy
Beyond the preview
Go deeper on NCT04699279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699279.